Table 1
Percentage of responders with treatment/placebo and numbers needed to treat (NNTs) after 2, 4, 8 and 12 weeks
| Outcome | Percentage of responders with treatment/placebo after different numbers of weeks | NNT (95% CI) | ||||||
| 2 | 4 | 8 | 12 | 2 | 4 | 8 | 12 | |
| Etoricoxib 30 mg; 5 trials, 1486 patients | ||||||||
| ⩾15% | 70/41 | 70/45 | 70/43 | 68/45 | 3.5 (2.9 to 4.2) | 4.1 (3.4 to 5.2) | 3.6 (3.0 to 4.4) | 4.4 (3.5 to 5.7) |
| ⩾30% | 54/27 | 56/30 | 59/31 | 59/36 | 3.7 (3.1 to 4.5) | 3.9 (3.3 to 4.9) | 3.7 (3.1 to 4.5) | 4.3 (3.5 to 5.6) |
| ⩾50% | 35/13 | 40/18 | 44/23 | 44/24 | 4.6 (3.8 to 5.6) | 4.4 (3.7 to 5.5) | 5.0 (4.0 to 6.5) | 5.1 (4.1 to 6.9) |
| ⩾70% | 17/5 | 22/9 | 26/13 | 28/17 | 8.9 (7.0 to 12) | 7.7 (6.0 to 11) | 7.8 (6.0 to 11) | 8.9 (6.3 to 15) |
| Etoricoxib 60 mg; 3 trials, 711 patients | ||||||||
| ⩾15% | 77/46 | 76/51 | 73/44 | 71/47 | 3.3 (2.6 to 4.5) | 4.1 (3.1 to 6.2) | 3.5 (2.7 to 4.9) | 4.2 (2.9 to 7.4) |
| ⩾30% | 61/31 | 63/32 | 60/30 | 59/35 | 3.2 (2.6 to 4.6) | 3.2 (2.6 to 4.4) | 3.3 (2.6 to 4.5) | 4.0 (2.9 to 6.7) |
| ⩾50% | 43/16 | 46/19 | 47/20 | 44/23 | 3.7 (2.9 to 5.0) | 3.7 (2.9 to 5.1) | 3.7 (2.9 to 5.1) | 4.7 (3.3 to 8.1) |
| ⩾70% | 25/4 | 27/9 | 30/11 | 30/15 | 4.7 (3.9 to 6.0) | 5.7 (4.3 to 8.4) | 5.3 (4.0 to 7.7) | 6.7 (4.4 to 14) |
| Celecoxib 200 mg; 2 trials, 714 patients | ||||||||
| ⩾15% | 64/42 | 67/45 | 64/40 | 64/40 | 4.6 (3.4 to 7.0) | 4.5 (3.3 to 6.7) | 4.2 (3.2 to 6.1) | 4.2 (3.2 to 6.1) |
| ⩾30% | 53/27 | 54/29 | 54/30 | 53/31 | 3.9 (3.0 to 5.3) | 4.0 (3.1 to 5.6) | 4.1 (3.2 to 5.9) | 4.7 (3.5 to 7.1) |
| ⩾50% | 30/12 | 39/18 | 39/22 | 39/22 | 5.6 (4.2 to 8.3) | 4.8 (3.6 to 6.9) | 5.9 (4.2 to 9.9) | 5.8 (4.2 to 9.5) |
| ⩾70% | 15/6 | 22/10 | 24/13 | 26/16 | 10 (7.1 to 18) | 8.7 (5.9 to 16) | 9.1 (6.0 to 19) | 10 (6.3 to 27) |
| Naproxen 1000 mg; 2 trials, 531 patients | ||||||||
| ⩾15% | 78/54 | 75/57 | 70/48 | 64/47 | 4.2 (3.0 to 7.5) | 5.6 (3.6 to 13) | 4.6 (3.1 to 8.8) | 5.9 (3.6 to 15) |
| ⩾30% | 63/35 | 65/36 | 60/35 | 55/35 | 3.5 (2.6 to 5.5) | 3.5 (2.6 to 5.4) | 3.9 (2.8 to 6.4) | 4.8 (3.2 to 9.2) |
| ⩾50% | 44/20 | 47/22 | 45/22 | 44/23 | 4.1 (3.0 to 6.3) | 3.9 (2.9 to 6.0) | 4.3 (3.1 to 7.0) | 4.8 (3.3 to 8.5) |
| ⩾70% | 22/5 | 27/10 | 28/12 | 27/15 | 5.9 (4.4 to 8.8) | 5.8 (4.1 to 9.7) | 6.1 (4.2 to 11) | 8.0 (4.9 to 21) |
| Ibuprofen 2400 mg; 2 trials, 618 patients | ||||||||
| ⩾15% | 69/43 | 65/47 | 60/48 | 58/49 | 3.8 (2.9 to 5.5) | 5.5 (3.8 to 10) | 7.8 (4.8 to 22) | 11 (5.8 to 121) |
| ⩾30% | 49/29 | 51/33 | 51/36 | 49/41 | 5.0 (3.6 to 8.1) | 5.6 (3.9 to 10) | 6.6 (4.3 to 14) | NS |
| ⩾50% | 29/14 | 35/20 | 40/24 | 39/27 | 6.5 (4.6 to 11) | 6.9 (4.6 to 14) | 6.4 (4.3 to 12) | 8.4 (5.1 to 24) |
| ⩾70% | 16/6 | 20/8 | 22/13 | 26/18 | 10 (7.0 to 21) | 7.9 (5.6 to 14) | 11 (6.6 to 32) | 13 (6.8 to 75) |
-
Response with placebo is for placebo groups from trials in the particular comparison being made.
